Sachiyo Yoshio

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1370284/sachiyo-yoshio-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42 684 16 25 g-index

50 889 6.6 avg, IF L-index

#	Paper	IF	Citations
42	Effects of SGLT2 inhibitor on tumor-releasing chemokines/cytokines in Hep3B and Huh7 cells <i>JGH Open</i> , 2022 , 6, 270-273	1.8	
41	Impact of Immune Reconstitution-Induced Hepatic Flare on Hepatitis B Surface Antigen Loss in Hepatitis B Virus/Human Immunodeficiency Virus-1 Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2021 , 223, 2080-2089	7	5
40	Prolonged Gut Dysbiosis and Fecal Excretion of Hepatitis A Virus in Patients Infected with Human Immunodeficiency Virus. <i>Viruses</i> , 2021 , 13,	6.2	1
39	Cluster of Differentiation 44 Promotes Liver Fibrosis and Serves as a Biomarker in Congestive Hepatopathy. <i>Hepatology Communications</i> , 2021 , 5, 1437-1447	6	2
38	Myostatin as a fibroblast-activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2021 , 51, 803-812	5.1	3
37	Hepatitis C virus modulates signal peptide peptidase to alter host protein processing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	2
36	Effects of a low-intensity resistance exercise program on serum miR-630, miR-5703, and Fractalkine/CX3CL1 expressions in subjects with No exercise habits: A preliminary study. <i>Hepatology Research</i> , 2021 , 51, 823-833	5.1	4
35	Pharmacotherapy options for managing hepatitis B in children. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 449-467	4	O
34	Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	4
33	Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients. <i>BMC Gastroenterology</i> , 2021 , 21, 55	3	3
32	Increased Frequency of Dysfunctional Siglec-7CD57PD-1 Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2021 , 12, 603133	8.4	3
31	Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. <i>Immunological Medicine</i> , 2021 , 44, 175-186	3.7	1
30	Dysregulated Expression of the Nuclear Exosome Targeting Complex Component Rbm7 in Nonhematopoietic Cells Licenses the Development of Fibrosis. <i>Immunity</i> , 2020 , 52, 542-556.e13	32.3	15
29	Increased frequency of PD-1+CD57+Siglec-7- dysfunctional NK cells in patients with nonalcoholic fatty liver disease <i>Journal of Clinical Oncology</i> , 2020 , 38, 589-589	2.2	
28	Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. <i>Global Health & Medicine</i> , 2020 , 2, 273-281	2.4	O
27	High Dose of Pegylated Interferon for the Treatment of Chronic Hepatitis B in Children Infected With Genotype C. <i>JPGN Reports</i> , 2020 , 1, e005	0.3	1
26	Serum soluble sialic acid-binding immunoglobulin-like lectin-7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2020 , 50, 466-477	5.1	4

(2016-2020)

25	Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
24	Liver disease secondary to congenital heart disease in children. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019 , 13, 651-666	4.2	13
23	Immune Determinants in the Acquisition and Maintenance of Antibody to Hepatitis B Surface Antigen in Adults After First-Time Hepatitis B Vaccination. <i>Hepatology Communications</i> , 2019 , 3, 812-82-	4 ⁶	4
22	High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma. <i>Hepatology Research</i> , 2019 , 49, 1046-1053	5.1	16
21	Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2019 , 54, 1007-1018	6.9	16
20	Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2019 , 9, 15788	4.9	9
19	USP15 Participates in Hepatitis C Virus Propagation through Regulation of Viral RNA Translation and Lipid Droplet Formation. <i>Journal of Virology</i> , 2019 , 93,	6.6	8
18	Tumor necrosis factor-Emediated hepatocyte apoptosis stimulates fibrosis in the steatotic liver in mice. <i>Hepatology Communications</i> , 2018 , 2, 407-420	6	15
17	Double-Stranded RNA Derived from Lactic Acid Bacteria Augments Th1 Immunity Interferon-Ifrom Human Dendritic Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 27	8.4	11
16	Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients. <i>JCI Insight</i> , 2018 , 3,	9.9	16
15	MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection. <i>Hepatology Research</i> , 2018 , 48, 313-321	5.1	20
14	Infection with flaviviruses requires BCLXL for cell survival. <i>PLoS Pathogens</i> , 2018 , 14, e1007299	7.6	18
13	Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2017 , 141, 1011-1017	7.5	5
12	Hepatitis Action Plan and Changing Trend of Liver Disease in Japan: Viral Hepatitis and Nonalcoholic Fatty Liver Disease. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2017 , 7, 60-64	1.6	4
11	Long noncoding RNA #32 contributes to antiviral responses by controlling interferon-stimulated gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 10388-93	11.5	65
10	Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016 , 6, 35282	4.9	55
9	Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016 , 6, 28814	4.9	32
8	Hepatocyte Factor JMJD5 Regulates Hepatitis B Virus Replication through Interaction with HBx. <i>Journal of Virology</i> , 2016 , 90, 3530-42	6.6	22

7	Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. <i>Hepatology</i> , 2016 , 63, 83-94	11.2	30
6	Host-virus interactions in hepatitis B and hepatitis C infection. <i>Journal of Gastroenterology</i> , 2016 , 51, 409-20	6.9	21
5	Association of serum IFN-B with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2015 , 50, 894-902	6.9	22
4	Ex vivo induction of IFN-B by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients. <i>Journal of Gastroenterology</i> , 2014 , 49, 126-37	6.9	16
3	Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection. <i>Journal of Gastroenterology</i> , 2013 , 48, 660	0 - 78	38
2	TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. <i>Hepatology</i> , 2013 , 57, 1416-25	11.2	98
1	Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-lin response to hepatitis C virus. <i>Hepatology</i> , 2013 , 57, 1705-15	11.2	74